[go: up one dir, main page]

WO2006061714A3 - Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis - Google Patents

Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis Download PDF

Info

Publication number
WO2006061714A3
WO2006061714A3 PCT/IB2005/003766 IB2005003766W WO2006061714A3 WO 2006061714 A3 WO2006061714 A3 WO 2006061714A3 IB 2005003766 W IB2005003766 W IB 2005003766W WO 2006061714 A3 WO2006061714 A3 WO 2006061714A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
anticoronaviral
synthesis
compounds
materials
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/003766
Other languages
French (fr)
Other versions
WO2006061714A2 (en
Inventor
Robert Steven Kania
Lennert Joseph Mitchell Jr
James A Nieman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of WO2006061714A2 publication Critical patent/WO2006061714A2/en
Publication of WO2006061714A3 publication Critical patent/WO2006061714A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to methods of inhibiting SARS-related coronavirus viral replication activity comprising contacting a SARS-related coronavirus protease with a therapeutically effective amount of a SARS 3C like protease inhibitor, and compositions comprising the same.
PCT/IB2005/003766 2004-12-09 2005-12-06 Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis Ceased WO2006061714A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63526504P 2004-12-09 2004-12-09
US60/635,265 2004-12-09

Publications (2)

Publication Number Publication Date
WO2006061714A2 WO2006061714A2 (en) 2006-06-15
WO2006061714A3 true WO2006061714A3 (en) 2006-08-24

Family

ID=36353814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003766 Ceased WO2006061714A2 (en) 2004-12-09 2005-12-06 Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis

Country Status (1)

Country Link
WO (1) WO2006061714A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11358953B2 (en) 2020-07-20 2022-06-14 Enanta Pharmaceuticals, Inc. Functionalized peptides as antiviral agents
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US11976084B2 (en) 2020-11-23 2024-05-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838523A (en) * 2011-06-23 2012-12-26 南开大学 Anti-enterovirus 71 (EV71) valerolactam compounds, preparation method and uses thereof
WO2013049382A2 (en) * 2011-09-27 2013-04-04 Kansas State University Research Foundation Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
EP2844249A4 (en) 2012-05-02 2016-03-09 Univ Kansas State MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C PROTEINS OF PICORNAVIRUS, CALICIVIRUS AND CORONAVIRUS
CN116655730A (en) 2016-06-01 2023-08-29 雅斯娜 Derivatives of N-caproic acid-L-tyrosine-L-isoleucine- (6) -aminocaproamide for the treatment of various diseases
TW201817714A (en) * 2016-08-30 2018-05-16 英商葛蘭素史密斯克藍智慧財產權有限公司 Compounds that inhibit 3C and 3CL proteases and methods of use thereof
CN110818691A (en) * 2018-08-09 2020-02-21 中国科学院上海药物研究所 Ketoamide compound and its preparation method, pharmaceutical composition and use
KR20220026538A (en) * 2019-06-05 2022-03-04 에모리 유니버시티 Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2021151387A1 (en) * 2020-01-31 2021-08-05 中国科学院上海药物研究所 Pharmaceutical use of ketoamide-based compound
WO2021188620A1 (en) * 2020-03-17 2021-09-23 Cocrystal Pharma Inc. Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
PH12021552872A1 (en) 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19
WO2021206876A1 (en) * 2020-04-10 2021-10-14 Cocrystal Pharma, Inc. Inhibitors of norovirus and coronavirus replication
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
WO2021216195A1 (en) * 2020-04-23 2021-10-28 Purdue Research Foundation Compounds for the treatment of sars
WO2022072504A1 (en) * 2020-09-29 2022-04-07 Healion Bio, Inc. Methods and compositions for the treatment of viral diseases
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CA3173333A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
EP4263502B1 (en) * 2020-12-18 2024-12-25 Nxera Pharma UK Limited Sars-cov-2 mpro inhibitor compounds
GB202107385D0 (en) * 2021-05-24 2021-07-07 Heptares Therapeutics Ltd Sars-cov-2 mpro inhibitor compounds
WO2022156693A1 (en) * 2021-01-19 2022-07-28 中国人民解放军军事科学院军事医学研究院 Viral protease inhibitor containing n-(substituted sulfonyl) acetamide structure and application thereof in antiviral drugs
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
KR20240057384A (en) * 2021-06-02 2024-05-02 아세아 테라퓨틱스 인코포레이티드 Protease inhibitors as antiviral agents
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023009187A1 (en) * 2021-07-29 2023-02-02 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
EP4387980A1 (en) * 2021-08-18 2024-06-26 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023107419A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
WO2023107417A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Heterocyclic antiviral agents
TW202334123A (en) * 2021-12-31 2023-09-01 大陸商蘇州愛科百發生物醫藥技術有限公司 Compounds, conjugates and methods thereof for preventing and treating coronavirus infection
WO2023196307A1 (en) 2022-04-05 2023-10-12 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
CN116535460A (en) * 2023-04-28 2023-08-04 中国人民解放军军事科学院军事医学研究院 Sulfur-containing peptidomimetic compounds, and preparation method and application thereof
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections
WO2025011656A1 (en) * 2023-07-13 2025-01-16 Shanghai Curegene Pharmaceutical Co., Ltd. Anticoronviral compounds and compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101742A2 (en) * 2003-05-06 2004-11-25 Cytovia, Inc Protease inhibitors for coronaviruses and sars-cov and the use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101742A2 (en) * 2003-05-06 2004-11-25 Cytovia, Inc Protease inhibitors for coronaviruses and sars-cov and the use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAIN ET AL.: "Synthesis and Evaluation of Keto-glutamine Analogues as Potent Inhibitors of Severe Acute respiratory syndrome 3CLpro", J. MED. CHEM., vol. 47, no. 25, 2 December 2004 (2004-12-02), pages 6113 - 6116, XP002382196 *
KALDOR S W ET AL: "Glutamine-derived aldehydes for the inhibition of human rhinovirus 3C protease", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 5, no. 17, 7 September 1995 (1995-09-07), pages 2021 - 2026, XP004135357, ISSN: 0960-894X *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11358953B2 (en) 2020-07-20 2022-06-14 Enanta Pharmaceuticals, Inc. Functionalized peptides as antiviral agents
US11976084B2 (en) 2020-11-23 2024-05-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents

Also Published As

Publication number Publication date
WO2006061714A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
WO2006061714A3 (en) Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
WO2008063671A3 (en) Heterobicyclic metalloprotease inhibitors
WO2008109177A3 (en) Metalloprotease inhibitors containing a heterocyclic moiety
WO2006091529A3 (en) A solid pharmaceutical dosage formulation
WO2007139856A3 (en) Heterobicyclic metalloprotease inhibitors
WO2007025307A3 (en) Inhibitors of serine proteases
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2010123919A3 (en) Piperidine inhibitors of janus kinase 3
WO2007139860A3 (en) Heterobicylic metalloprotease inhibitors
IL187453A0 (en) The preparation and uses of compounds as aspartyl protease inhibitors
WO2009082701A8 (en) Hcv protease inhibitors and uses thereof
JP2007504142A5 (en) Solid drug dosage form comprising HIV protease inhibitor solid dispersion
MX2008001799A (en) Pharmaceutical composition comprising a dpp-iv inhibitor.
WO2005077103A3 (en) Compositions and methods for modification and prevention of sars coronavirus infectivity
CL2007000918A1 (en) COMPOUNDS DERIVED FROM ENFUMAFUNGINA, INHIBITORS OF (1,3) -BETA-D-GLUCANOSINTETASE; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT A FUNGICAL INFECTION.
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof
WO2007130822A3 (en) Mglur5 modulators iii
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2006124684A3 (en) Combination therapy comprising a taxane and a thymidylate synthase inhibitor
WO2005075467A3 (en) Crystalline forms of zolmitriptan
WO2007067784A3 (en) Liposomal compositions
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2006134499A3 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
IL182601A0 (en) The use of a protease or a protease inhibitor for the manufacture of medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05818498

Country of ref document: EP

Kind code of ref document: A2